nnc0365-3769 a
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jan 8, 2020 (NCT04204408)
Timeline
Indications
Mechanism of action
- Coagulation factor VIIIINHIBITOR
F8 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05878938 | Phase 3 | Jun 26, 2023 | Novo Nordisk |
| NCT05681845 | Phase 1 | Jan 2, 2023 | Novo Nordisk |
| NCT05053139 | Phase 3 | Dec 2, 2021 | Novo Nordisk |
| NCT04204408 | Phase 1/Phase 2 (Phase 2) | Jan 8, 2020 | Novo Nordisk |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 4 | 4 | 3 | 2020 |
1 organizations
Page 1 / 1